What is Vesugen? The Vascular Bioregulatory Peptide

Vesugen is a short three-amino-acid peptide (Lys–Glu–Asp) studied as a tissue-specific 'bioregulator' for the vascular endothelium and brain. It belongs to a family of ultrashort peptides investigated for epigenetic control of gene expression — through binding to DNA promoter motifs and/or histone proteins — to influence functions specific to each cell type.

The proposed mechanism of KED is epigenetic regulation of gene transcription through direct interactions with DNA and nucleosomal histones — a behavior documented repeatedly for ultrashort peptides in vitro, in silico, and with biophysical methods. In endothelial models, KED normalized EDN1, restored connexins (e.g., Cx37/Cx40/Cx43), and increased SIRT1 — changes associated with vasoprotective phenotypes.

In endothelial and vascular injury models, KED showed gene-level changes compatible with improved microvascular homeostasis. Preclinical studies report EDN1 normalization, connexin re-expression, and SIRT1 increases, together suggesting improved endothelial communication and anti-aging signaling. More independent replication is needed.

In Alzheimer's disease (AD) models, KED maintained dendritic spines and improved dendritic tree metrics in vitro and in the 5xFAD mouse model, while regulating neurogenesis and cell cycle gene expression (e.g., NES, GAP43, p16/p21). A 2024 study in induced neurons from elderly donors reported enhanced dendritic complexity with KED.

Human evidence is limited and heterogeneous. A small Russian geriatric study suggests oral Pinealon + Vesugen improved cognitive/functional metrics in workers exposed to harmful conditions, and a separate clinical report recommended these peptides as 'geroprotective'. These findings require larger, controlled replication.

For single-use reconstitution, sterile water for injection is typically used. For multi-draw vials, bacteriostatic water (sterile water with 0.9% benzyl alcohol) is common. Warm the sealed vial to room temperature before opening, reconstitute to a validated working concentration (e.g., 1–2 mg/mL) with aseptic technique. Mix gently, avoid foaming. Prepare single-dose aliquots to minimize freeze-thaw cycles.